Johnson & Johnson closed $25.19 below its 52-week high ($168.85), which the company reached on September 4th.

Discover why JNJ's long-term buy rating is supported by its blue-chip status, profitability, and diverse revenue lines, ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.

Johnson & Johnson (JNJ) stock saw a modest uptick, ending the day at $144.19 which represents a slight increase of $0.17 or 0.12% from the prior close of $144.02. The stock opened at $144.07 and ...